NCT02626741

Brief Summary

The purpose of this study is to determine whether meal replacement, SlimWell ®, is effective in the treatment of obesity patients with metabolic syndrome.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
138

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Feb 2015

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

December 4, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 10, 2015

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2016

Completed
Last Updated

December 10, 2015

Status Verified

December 1, 2015

Enrollment Period

1 year

First QC Date

December 4, 2015

Last Update Submit

December 8, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Participants with weight loss unit in kilograms

    Change from baseline body weight at 3 months

    3 months

Secondary Outcomes (3)

  • Participants with waist circumference change in centimeters

    3 months

  • Participants with triglyceride change in mg/dl.

    3 months

  • Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study meal replacement, Graded According to NCI CTCAE Version 3.0

    3 months

Study Arms (2)

meal replacement group

EXPERIMENTAL

the participants receive a meal replacement plus life style modification

Dietary Supplement: meal replacement groupBehavioral: control group

control group

EXPERIMENTAL

the participants receive life style modification only.

Behavioral: control group

Interventions

meal replacement groupDIETARY_SUPPLEMENT

The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.

Also known as: SlimWell
meal replacement group
control groupBEHAVIORAL

The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.

Also known as: only life style modification
control groupmeal replacement group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Body mass index more than or equal to 25 kg/m2
  • Patients with metabolic syndrome
  • Patients who are on anti-hypertensive drugs, oral hypoglycemic drugs and lipid lowering drugs.

You may not qualify if:

  • Uncontrolled diabetes patients
  • Patients with gastrointestinal abnormalities
  • Patients with cardiovascular diseases
  • Patients with hematologic disorders
  • Patients with Glomerular filtration rate less than 60 ml/min/1.73m2
  • Patients with drug or alcohol abuse
  • Pregnancy and lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine Siriraj Hospital, Mahidol University

Bangkok, Bangkok, 10700, Thailand

RECRUITING

Related Publications (1)

  • Leader NJ, Ryan L, Molyneaux L, Yue DK. How best to use partial meal replacement in managing overweight or obese patients with poorly controlled type 2 diabetes. Obesity (Silver Spring). 2013 Feb;21(2):251-3. doi: 10.1002/oby.20057.

    PMID: 23404963BACKGROUND

MeSH Terms

Conditions

Abdominal obesity metabolic syndrome

Interventions

Control Groups

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Kusuma Chaiyasoot, MD

    Mahidol University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kusuma Chaiyasoot, MD

CONTACT

Preyanuj Yamwong, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 4, 2015

First Posted

December 10, 2015

Study Start

February 1, 2015

Primary Completion

February 1, 2016

Study Completion

April 1, 2016

Last Updated

December 10, 2015

Record last verified: 2015-12

Locations